Leadership Team

Bruce Goldsmith, Ph.D. , Chief Executive Officer

Bruce A. Goldsmith, Ph.D., M.B.A. has served as our Chief Executive Officer and President and as a member of our board of directors since January 2020. Dr. Goldsmith served as an Advisor and Venture Partner at Deerfield Ventures from January 2019 to January 2020. From April 2019 to January 2020, Dr. Goldsmith also served as Interim Chief Executive Officer of Civetta Therapeutics. Prior to that, Dr. Goldsmith served initially as Chief Business Officer and then as Chief Operating Officer at Lycera, Corp. from April 2013 to January 2019. From 2008 to 2012, Dr. Goldsmith served as Vice President and then Senior Vice President of Corporate Development at Allos Therapeutics. Prior to Allos, Dr. Goldsmith served in various leadership roles at GPC Biotech in 2007 and Tibotec Therapeutics, a subsidiary of Johnson & Johnson, from 2005 to 2007. Dr. Goldsmith also previously held various positions at Johnson & Johnson in oncology global strategic marketing, business development and licensing and acquisition finance. Prior to joining Johnson & Johnson, Dr. Goldsmith was a research fellow at Novartis Pharma, K.K., where he conducted scientific research in a neurodegeneration drug discovery group. Dr. Goldsmith received a B.A. in Biology from Colgate University, a Ph.D. in Biology with a research thesis in neuroscience from the University of Pennsylvania, and an M.B.A. from Columbia University. We believe that Dr. Goldsmith is qualified to serve on our board of directors due to his experience in the biopharmaceutical and biotechnology industry.

Jill M. Quigley, J.D., Chief Operating Officer

Jill M. Quigley has served as our Chief Operating Officer since November 2018. From 2017 to 2018, Ms. Quigley served as Chief Executive Officer and General Counsel of Nutrinia Ltd., a pharmaceutical company focused on the treatment of rare conditions of the gastrointestinal tract. From 2012 to 2016, Ms. Quigley served as Senior Counsel of NPS Pharmaceuticals, a biotechnology company focused on developing treatments for rare diseases, which was acquired by Shire plc in March 2015. From 2011 to 2012, Ms. Quigley served as Corporate Counsel for Pharmasset, Inc., a pharmaceutical company. Ms. Quigley began her career as an associate with the law firm of Dechert LLP and later served as Assistant Corporate Counsel for Integra LifeSciences Holdings Corporation. Ms. Quigley currently serves on the board of directors for Terns Pharmaceuticals, Inc. She received a B.A. in Communications, Legal Institutions, Economics & Government (CLEG) from American University and a J.D. from Rutgers School of Law.

Alex Fotopoulos, MBA, Chief Technical Officer

Alex Fotopoulos, MSc., MBA, has served as our Chief Technical Officer since July 2019. From November 2017 to July 2019, Mr. Fotopoulos served as Senior Vice President, Technical Operations, Gene Therapy of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company. From May 2016 to November 2017, Mr. Fotopoulos served as Senior Vice President, Technical Operations of Dimension Therapeutics, Inc., a biotechnology company, acquired by Ultragenyx Pharmaceutical Inc., focusing on the development of gene therapy for rare diseases associated with the liver and caused by genetic mutations. From August 2011 to May 2016, Mr. Fotopoulos served in various senior leadership roles at Momenta Pharmaceuticals, Inc., a biotechnology company, including Vice President, Technical Operations and Senior Director, Technical Operations. Prior to that, Mr. Fotopoulos served for 18 years in various senior leadership roles at Biogen, Inc., a biotechnology company, including Senior Director, Global Manufacturing Engineering and Director, Global Engineering Technology. Mr. Fotopoulos received a Diploma in Chemical Engineering at the National Technical University of Athens, Greece, a M.Sc. in Chemical Engineering from Tufts University, and a M.B.A. in General Management from the F.W. Olin Graduate School of Business at Babson College.

Edgar B. (Chip) Cale, J.D., General Counsel and Corporate Secretary

Edgar B. (Chip) Cale, has served as our General Counsel since September 2019 and Corporate Secretary since December 2019. From June 1998 to July 2019, Mr. Cale served in various senior leadership roles at GlaxoSmithKline plc, a multinational pharmaceutical company, including Senior Vice President, Legal Corporate Functions; Vice President, Associate General Counsel, Legal Operations, WWBD; Vice President, General Counsel, GSK Vaccines; and Assistant General Counsel. Prior to that, Mr. Cale served as a corporate and securities lawyer supporting emerging growth companies in the life science and technology industries at Venture Law Group LLP and Brobeck, Phleger & Harrison LLP. Mr. Cale received a B.S. in Biology from the University of Pennsylvania and a J.D. from the University of California, Berkeley.

Eliseo Oreste Salinas, M.D., MSc, Chief Research and Development Officer

Eliseo Oreste Salinas, M.D., MSc, has served as our chief research & development (R&D) officer since March 2021. He joined our company from Acadia Pharmaceuticals, where was chief scientific officer (CSO), senior vice president and head of External Innovation since September 2018. Dr. Salinas has 30 years of experience developing diverse therapeutic products for central nervous system and other disorders, spanning small molecules, biologics and cell therapy. He has been directly involved with numerous investigational new drug (IND) applications and 15 regulatory approvals. For the last 17 years of his career, Dr. Salinas has managed R&D organizations in mid-size companies, such as Shire and Elan Pharmaceuticals, where he was executive vice president, R&D and CSO, and executive vice president, head of development and chief medical officer, respectively. He also has managed R&D at small pharmaceutical and biotechnology companies, including Adolor, StemCell Inc. and New World Laboratories. Dr. Salinas received his M.D. from the University of Buenos Aires, Argentina, completed his residency in psychiatry at the Clinique des Maladies Mentales et de l'Encéphale, Paris, and obtained his Master of Science degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris.

James M. Wilson, M.D., Ph.D., Chief Scientific Advisor

James M. Wilson, M.D., Ph.D. is the Director of the Gene Therapy Program; Rose H. Weiss Professor and Director of the Orphan Disease Center and Professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wilson will serve as Chief Scientific Advisor at Passage Bio. Dr. Wilson’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 550 papers and is named on over 110 patents. After launching his faculty career in the Howard Hughes Medical Institute at the University of Michigan, he moved to the University of Pennsylvania in 1993. Dr. Wilson completed his training in Internal Medicine at the Massachusetts General Hospital followed by a postdoctoral fellowship at the Whitehead Institute, where he began his work in gene therapy.